What a difference a year makes. In the first half of 2024, the MedTech sector showed a notable uptick in M&A activity, with 114 acquisitions valued at $40.3 billion — close to last year’s total. Despite fewer venture rounds, funding remained strong at $9.7...
The JPM Q1 2024 MedTech Licensing and Venture report highlights the first quarter of 2024 and shows promising developments in the MedTech investment landscape. There are indications of a potential recovery and growth compared to previous years. Can we be so lucky?...
In the ever-evolving landscape of MedTech and Life Sciences, where innovation and technological advancement are at the forefront, success isn’t strictly about the devices themselves, but it’s also about the people who bring them to life. The brilliant minds...
A CONVERSATION WITH RENOWNED VASCULAR SURGEON, DR. FRANK J. VEITH As one of America’s most celebrated surgeons, Dr. Frank Veith’s career was anything but conventional – he’s worked undercover for the CIA, attempted to make Vascular Surgery an independent specialty,...
MEDTECH + LIFE SCIENCES OUTLOOK IN 2023 2022 was an interesting year, to say the least. It was the tale of two markets. After the extremely volatile years of 2020 and 2021, no one could have predicted the sheer amount of momentum that lay ahead in 2022. The economy...
Heading into 2022, many expected the rapid continuation of strong initial public offerings (IPOs) and merger + acquisition (M+A) activity. Wow, that was off. The underestimated implications of supply chain issues, geopolitical concerns, and Federal Trade Commission...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy policyOkNo
